Speller J C, Barnes T R, Curson D A, Pantelis C, Alberts J L
Plymouth Nuffield Clinic, Devon.
Br J Psychiatry. 1997 Dec;171:564-8. doi: 10.1192/bjp.171.6.564.
Amisulpride is a potent substituted benzamide antipsychotic drug claimed to improve the negative symptoms of schizophrenia, particularly at low dosage.
Sixty long-term in-patients with schizophrenia and selected for predominant negative symptoms were randomised to receive either haloperidol or amisulpride. Over a year there was systematic dose reduction, as symptoms allowed.
There were no significant differences between the treatment groups in the proportion receiving low-dose treatment, the control of positive symptoms, or ratings of social behaviour, side-effects or tardive dyskinesia. For negative symptoms, there were consistent but non-significant trends in favour of amisulpride. The amisulpride patients required significantly less anticholinergic medication.
In chronically-hospitalised in-patients with schizophrenia characterised by persistent negative symptoms, amisulpride was a well-tolerated maintenance antipsychotic medication. The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction.
氨磺必利是一种强效的取代苯甲酰胺类抗精神病药物，据称尤其在低剂量时可改善精神分裂症的阴性症状。
60名长期住院的以阴性症状为主的精神分裂症患者被随机分为接受氟哌啶醇或氨磺必利治疗。在一年时间里，根据症状允许情况进行系统性的剂量减少。
治疗组在接受低剂量治疗的比例、阳性症状的控制、社会行为评分、副作用或迟发性运动障碍方面没有显著差异。对于阴性症状，有持续但不显著的趋势表明氨磺必利更具优势。氨磺必利组患者所需的抗胆碱能药物明显更少。
在以持续阴性症状为特征的慢性住院精神分裂症患者中，氨磺必利是一种耐受性良好的维持性抗精神病药物。尽管减少了剂量，但该药物在减轻阴性症状方面效果有限，阴性症状在这个样本中是相对稳定、持久的现象。
